Viridian Appoints Scott Myers as President and Chief Executive Officer
Viridian Therapeutics has appointed Scott Myers as President and Chief Executive Officer, as well as a member of the Board of Directors, effective February 6, 2023. He succeeds Jonathan Violin, PhD, who has led Viridian since its inception in 2020.
“Our progress and growth since founding Viridian have been nothing but extraordinary. With our first phase 3 trial in TED underway, and a potential best-in-class subcutaneous strategy advancing rapidly behind it, the time is right to advance the company through its next stage of growth,” Dr. Violin, Viridian’s co-founder and founding CEO, said in a company news release. “Scott brings to Viridian extensive late-stage clinical development, global commercial, and executive leadership experience with a proven track record of creating value. His appointment puts Viridian in a position to build upon the company’s strong foundation to achieve our shared vision of becoming a fully-integrated biopharmaceutical company. I am proud of what we have built at Viridian, and excited about the future of the company under Scott’s leadership.”
Mr. Myers has more than 30 years of biopharmaceutical and medical technology experience, and has held global executive leadership and director roles at numerous commercial and development-stage biopharmaceutical companies. Mr. Myers most recently served as the CEO and Director of AMAG Pharmaceuticals, where he led its turnaround and strategic sale to Covis Pharma. Prior to AMAG, he served as CEO and Chairman of the Board of Rainier Therapeutics, a late-stage oncology company. Previous roles include serving as CEO, President and Director of Cascadian Therapeutics until its acquisition by Seagen, and as CEO of Aerocrine AB, a medical technology company. While CEO of these companies, Mr. Myers and his teams transformed the companies to focus on creating and advancing innovative products to deliver significant shareholder value.
“I am honored to lead Viridian at this exciting time of continued growth. I look forward to building on the remarkable accomplishments that Jonathan and the leadership team have achieved, and to executing on our vision of evolving Viridian into a fully-integrated biopharmaceutical company,” said Mr. Myers. “Viridian has a unique opportunity to bring differentiated medicines to market for patients suffering from TED, and to broaden and advance a pipeline of promising next-generation medicines for other serious and rare diseases. The team and I will be focused on clinical execution for our lead programs in TED, and on building our initial commercial team for Viridian’s future phases of growth.”